Karyopharm Therapeutics Inc. (KPTI): Results of Operations and Financial Condition
Karyopharm Therapeutics Inc. (KPTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 kpti-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission – Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis u
How this was made
The 30-second read
Why it matters
Traders can frame positioning around (1) the August sNDA submission and (2) whether FDA acceptance and Priority Review are granted, while monitoring how the reaffirmed revenue range and XPOVIO commercial performance influence near-term expectations.
Market read
The filing combines Q2 financials with a specific regulatory milestone for an August sNDA, which can drive near-term repricing of probability-weighted approval timelines.
What to watch
Guidance is reaffirmed but not raised; the market may still discount the probability of Priority Review or FDA acceptance timing, making the stock sensitive to any procedural delays.
Background
This is an SEC 8-K (Item 2.02) with Q2 2026 financial results and an update on Karyopharm’s myelofibrosis supplemental NDA plan for selinexor plus ruxolitinib.
Ticker impact
Karyopharm reports Q2 2026 results and reiterates an August sNDA submission for selinexor plus ruxolitinib in myelofibrosis under Accelerated Approval.
Bias to upside into the August submission/acceptance window if investors view the SVR35 surrogate-endpoint support as de-risking survival readout.
The filing discloses concrete financial datapoints (Q2 revenue, reaffirmed full-year guidance) and a specific regulatory milestone (August sNDA, Priority Review intent) plus FDA feedback that SVR35 can support an sNDA.
Market effects
Reinforces investor focus on accelerated-approval strategies in hematologic oncology and the market value of surrogate endpoints supported by FDA.
Limited direct regional read-through; growth is partly driven by ex-U.S. royalty expansion.
Potential global regulatory follow-ons with partners if the U.S. sNDA progresses, but the immediate driver is U.S. FDA review timing.
Counterpoint
The endometrial cancer Phase 3 XPORT-EC-042 failed its primary endpoint, which could temper enthusiasm for the broader selinexor pipeline despite myelofibrosis progress.
Key entities
- issuerKaryopharm Therapeutics Inc.
Commercial-stage oncology company reporting Q2 2026 results and updating its myelofibrosis sNDA plan for selinexor plus ruxolitinib.
- productXPOVIO (selinexor)
Karyopharm’s marketed therapy whose U.S. net product revenue and ex-U.S. royalty growth are highlighted.
- regulatorFDA
Provided written feedback that SVR35 can qualify as a reasonably likely surrogate endpoint to support an sNDA submission.
- clinical_programSENTRY trial
Phase 3 myelofibrosis program whose results were presented at ASCO and published in the Journal of Clinical Oncology.
